AQR Arbitrage LLC Buys 175,311 Shares of Amedisys, Inc. (NASDAQ:AMED)

AQR Arbitrage LLC grew its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 59.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 471,965 shares of the health services provider's stock after buying an additional 175,311 shares during the quarter. Amedisys accounts for approximately 0.9% of AQR Arbitrage LLC's holdings, making the stock its 22nd largest position. AQR Arbitrage LLC owned approximately 1.44% of Amedisys worth $42,812,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Trexquant Investment LP increased its position in shares of Amedisys by 1,317.8% during the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock valued at $7,964,000 after purchasing an additional 81,532 shares during the last quarter. ABC Arbitrage SA purchased a new stake in shares of Amedisys in the 4th quarter worth $2,522,000. Oddo BHF Asset Management Sas bought a new position in Amedisys in the 3rd quarter worth $7,238,000. Empowered Funds LLC purchased a new position in Amedisys during the fourth quarter valued at $318,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Amedisys during the fourth quarter valued at about $590,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Price Performance

NASDAQ AMED traded down $0.10 during trading hours on Tuesday, reaching $96.16. The company's stock had a trading volume of 230,275 shares, compared to its average volume of 413,746. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of 38.14, a PEG ratio of 1.78 and a beta of 0.96. The firm's 50-day moving average price is $92.67 and its 200-day moving average price is $91.69.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Amedisys's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.03 earnings per share. On average, equities research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AMED has been the subject of a number of recent research reports. Stephens reiterated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Amedisys has an average rating of "Hold" and a consensus target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.